Brucella abortusinduces TNF-α-dependent astroglial MMP-9 ...
Mercaptopurine/TNF-α inhibitors
1
Reactions 1319 - 18 Sep 2010 S Mercaptopurine/TNF-α inhibitors Myelodysplasia and leukaemia: 2 case reports Two patients developed myelodysplasia (MDS) and leukaemia respectively during treatment with mercaptopurine and TNF-α inhibitor therapy [drug(s) not specified] for Crohn’s disease. A 14-year-old boy presented with new bloody diarrhoea in June 2001. Prednisolone was stopped and oral mercaptopurine 50 mg/day was started. In April 2003 he presented with persistent diarrhoea and weekly IV TNF-α inhibitor therapy (100 mg) was commenced. He became transfusion-dependent in May 2003 and bone marrow investigation detected MDS-erythrodysplasia with monosomy 7. An enzyme test revealed thiopurine methyltransferase (TMPT) heterozygosity. He received a haematopoietic stem cell transplant (HSCT) in November 2004 and was well about 5 years later. A 21-year-old woman initially received prednisone, and then mesalazine and budesonide were initiated. She started on oral mercaptopurine 50 mg/day in September 2007. In December 2008 she presented with severe diarrhoea and began TNF-α inhibitor therapy [route and dosage not stated ]. In May 2009 she developed a fever and laterocervical lymphadenopathy. Investigations revealed a WBC count of 15 800/µL, a haemoglobin level of 10 g/dL and a platelet count of 88 000/µL. She was diagnosed with acute myeloid leukaemia and started a chemotherapy regime. She remained well 8 months after an HSCT. Piccin A, et al. Immunosuppressive treatments in Crohn's disease induce myelodysplasia and leukaemia. American Journal of Hematology 85: 634, No. 8, Aug 2010 - Italy 803038171 1 Reactions 18 Sep 2010 No. 1319 0114-9954/10/1319-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved
Transcript of Mercaptopurine/TNF-α inhibitors
Reactions 1319 - 18 Sep 2010
SMercaptopurine/TNF-α inhibitors
Myelodysplasia and leukaemia: 2 case reportsTwo patients developed myelodysplasia (MDS) and
leukaemia respectively during treatment withmercaptopurine and TNF-α inhibitor therapy [drug(s) notspecified] for Crohn’s disease.
A 14-year-old boy presented with new bloody diarrhoeain June 2001. Prednisolone was stopped and oralmercaptopurine 50 mg/day was started. In April 2003 hepresented with persistent diarrhoea and weekly IV TNF-αinhibitor therapy (100 mg) was commenced. He becametransfusion-dependent in May 2003 and bone marrowinvestigation detected MDS-erythrodysplasia withmonosomy 7. An enzyme test revealed thiopurinemethyltransferase (TMPT) heterozygosity. He received ahaematopoietic stem cell transplant (HSCT) in November2004 and was well about 5 years later.
A 21-year-old woman initially received prednisone, andthen mesalazine and budesonide were initiated. She startedon oral mercaptopurine 50 mg/day in September 2007. InDecember 2008 she presented with severe diarrhoea andbegan TNF-α inhibitor therapy [route and dosage not stated]. In May 2009 she developed a fever and laterocervicallymphadenopathy. Investigations revealed a WBC count of15 800/µL, a haemoglobin level of 10 g/dL and a plateletcount of 88 000/µL. She was diagnosed with acute myeloidleukaemia and started a chemotherapy regime. Sheremained well 8 months after an HSCT.Piccin A, et al. Immunosuppressive treatments in Crohn's disease inducemyelodysplasia and leukaemia. American Journal of Hematology 85: 634, No. 8,Aug 2010 - Italy 803038171
1
Reactions 18 Sep 2010 No. 13190114-9954/10/1319-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved
